Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines

CONCLUSIONS: In Canada, publicly funded pediatric PCV13 use was associated with large declines in IPD due to vaccine serotypes. Substantial residual PCV13-serotype IPD proportions observed among all ages imply limits to indirect protection afforded by the pediatric PCV13 program at the current uptake level and suggest the adult PPSV23 program alone is insufficient. Higher-valent PCVs have the potential to address a substantial proportion of remaining IPD cases among all age groups.PMID:33824041 | DOI:10.1016/j.vaccine.2021.02.069

Source: Vaccine - April 7, 2021 Category: Allergy & Immunology Authors: Stephane B Dion Maria Major Ana Gabriela Grajales Rajeev M Nepal Alejandro Cane Bradford Gessner Jelena Vojicic Jose A Suaya Source Type: research